We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
IBT.LSE

Price
692.00
Stock movement up
+- (%)
Company name
International Biotechnology Trust plc
Exchange
(LSE
,
Currency
GBX
)
Sector
Healthcare >
Biotechnology
Markedsverdi
25.10B
Ent verdi
25.12B
Pris/omsetning
647.91
Pris/bok
88.94
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
57.43%
Etterfølgende P/E
742.68
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
5.49%
3 års avkastning
-0.14%
5 års avkastning
2.29%
10 års avkastning
3.16%
Sist oppdatert: 2025-01-11

UTBYTTE

IBT.LSE betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E742.68
Pris til OCF557.24
Pris til FCF883.73
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning647.91
Pris til bok88.94
EV i forhold til salg648.31

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall36.28M
EPS (TTM)0.92
FCF per aksje (TTM)0.77

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)38.75M
Bruttofortjeneste (TTM)36.55M
Driftsinntekter (TTM)34.34M
Netto inntekt (TTM)33.80M
EPS (TTM)0.92
EPS (1 år fremover)-

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)94.32%
Driftsmargin (TTM)88.63%
Fortjenestemargin (TTM)87.24%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter10.43M
Netto fordringer99.00K
Samlede omløpsmidler10.65M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler308.15M
Leverandørgjeld1.87M
Kortsiktig/nåværende langsiktig gjeld22.83M
Sum kortsiktig gjeld0.00
Sum gjeld25.89M
Aksjonærenes egenkapital282.26M
Netto varige driftsmidler0.00

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)45.05M
Kapitalutgifter (TTM)16.64M
Fri kontantstrøm (TTM)28.41M
Utbetalt utbytte (TTM)16.31M

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning11.98%
Avkastning på eiendeler10.97%
Avkastning på investert kapital11.08%
Kontantavkastning på investert kapital9.31%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning697.00
Daglig høy700.00
Daglig lav684.00
Daglig volum68K
Tidenes høyeste858.00
1 år analytikerestimat-
Beta0.21
EPS (TTM)0.92
Utbytte per aksje-
Ex-div dato19 Dec 2024
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
IBT.LSES&P500
Nåværende prisfall fra toppnotering-19.35%-4.49%
Høyeste prisfall-92.23%-56.47%
Dato for høyeste fall8 Dec 19989 Mar 2009
Gj.snittlig fall fra topp-42.14%-11.12%
Gj.snittlig tid til ny topp50 days12 days
Maks tid til ny topp4295 days1805 days
SELSKAPSOPPLYSNINGER
IBT.LSE (International Biotechnology Trust plc) company logo
Markedsverdi
25.10B
Markedsverdi kategori
Large-cap
Beskrivelse
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the
Ansatte
0
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
UK
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Ingen gjenstander funnet